Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

41.23
+0.85002.11%
Pre-market: 41.890.6600+1.60%07:14 EDT
Volume:1.56M
Turnover:66.31M
Market Cap:2.94B
PE:-13.25
High:44.94
Open:41.23
Low:40.49
Close:40.38
52wk High:94.90
52wk Low:20.04
Shares:71.31M
Float Shares:54.64M
Volume Ratio:1.26
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1128
EPS(LYR):-2.3852
ROE:-20.21%
ROA:-14.95%
PB:2.17
PE(LYR):-17.29

Loading ...

Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Aug 07

Structure Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Structure Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Structure Therapeutics Inc. Q2 Net Income USD -106.159 Million

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GlobeNewswire
·
Aug 07

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewswire
·
Aug 03

Structure Therapeutics CSO Lin Xichen Disposes of USD 401,255.43 in Common Shares

Reuters
·
Jul 16

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?

Macro World​
·
Jul 06

Structure Therapeutics shareholders elect directors at annual meeting

Reuters
·
Jun 19

Why Structure Therapeutics (GPCR) Is Up 13.7% After Phase 2b Obesity Data Hit Nature Medicine And ADA

Simply Wall St.
·
Jun 16

XtalPi Biopharma GPCR Pact Tests AI Drug Discovery And Revenue Potential

Simply Wall St.
·
Jun 14

Nxera Pharma Joins OpenFold AI Consortium to Boost GPCR Drug Discovery

TIPRANKS
·
Jun 10

XtalPi Strikes US$400 Million GPCR Drug Discovery Pact with Global Biopharma Partner

TIPRANKS
·
Jun 09

XTALPI Forges Strategic AI Drug Discovery Alliance Valued Over $400M with Global Pharma Leader for Oral GPCR Therapy

Stock News
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Jun 08

How Phase 2b Oral GLP-1 Data and Phase 3 Plans Will Impact Structure Therapeutics (GPCR) Investors

Simply Wall St.
·
Jun 08

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Dow Jones
·
Jun 07

Structure's experimental obesity pill shows no signs of liver injury

Reuters
·
Jun 06

Structure Therapeutics - Aleniglipron Shows up to 16.2% Weight Loss Beyond 36 Weeks in Phase 2B Trial

THOMSON REUTERS
·
Jun 06